Thanks Sauce, that's good news. I had asked JJ to inquire about collaboration between CYGX and VGX at the SHM. Here are the PRs that I've looked at:
------------------------------------------------------
Malaga, Spain – May 23, 2007 –
VGX Pharmaceuticals’ novel pandemic influenza vaccine candidates triggered protective immune responses in pre-clinical challenge studies, according to data presented for the first time today at the Third International Conference on DNA Vaccines in Malaga, Spain.
VGX scientists created four synthetic consensus DNA vaccines to protect against a lethal Vietnamese H5N1 strain of avian influenza in mice. One of the vaccines resulted in complete protection of mice from death and illness of the challenge while 2 others had 60-80% protective effects. All of the vaccines were delivered using VGX’s proprietary CELLECTRA™ DNA Delivery Device. CELLECTRA™ is a novel adaptive electroporation device developed by VGX. The avian flu data was presented by Dr. Ruxandra Draghia-Akli, VGX Vice President, Immune Therapeutics Research.
Separately at the opening plenary session, Professor David B. Weiner of the University of Pennsylvania, Conference Chairman and a Co-founder of VGX, presented new data showing extensive T-cell mediated immune responses to VGX’s HIV vaccine candidates delivered with CELLECTRA™ in non-human primates. Most notably, the monkeys immunized with VGX vaccines displayed HIV-specific T cell responses as much as 10-20 fold greater than those reported in the literature using other vaccine modalities. Induction of high levels of T cell immune responses, especially the CD8+ Killer T cell responses, has long been thought to be important for developing a successful vaccine for HIV.
VGX plans to conduct further preclinical studies for both the HIV and Avian Flu vaccines, including the IND-enabling toxicology studies in 2007.
-----------------------------------------------
Houston, TX (May 23, 2007) CytoGenix, Inc. (CYGX.OB) announced today that Dr. Yin Chen, Chief Scientific Officer will present an update on preclinical animal data for DNA vaccines made using the Company's proprietary synDNA™ technology at the 2007 DNA Vaccines conference to be held in Malaga, Spain between May 23 and May 25.
Dr. Chen comments, "We have successfully conducted tests of synDNA™ based vaccines in mice, rabbits and non-human primates. The data to be presented will demonstrate the stimulation of the immune response comparing synDNA™ based vaccines to traditional plasmid DNA vaccines designed for the prevention of seasonal flu, HIV, smallpox and Hepatitis B. The tests indicate that the immune response triggered by synDNA™ vaccines is comparable to, and in some cases more effective than responses mediated by plasmid DNA. Data will also be shown demonstrating the effectiveness of a novel vaccine that protects against a highly virulent form of avian (bird) flu in animal challenge studies. These challenge experiments demonstrated that synDNA™ is just as effective as plasmid in mediating a protective immune response when the host is attacked by virulent viruses.
-----------------------------------------------
CYGX: Completes Pilot Study w/Novel synDNA(TM) Vaccine for Avian Influenza (APR 04, 2007)
CytoGenix, Inc. (CYGX) announced that it has successfully completed a pilot study with a novel synDNA(TM) vaccine designed for humans (therapeutic) and intended to protect against the avian (H5N1) influenza virus. The study demonstrated a robust protective effect in mice treated with the Company's synDNA(TM) vaccine whereas all the untreated control animals died after both groups were challenged with a highly virulent strain of avian influenza virus (Vietnam/1203/04).
-------------------------------------------------
HOUSTON--(BUSINESS WIRE 12/12/2006)--CytoGenix (OTCBB:CYGX) has demonstrated that a synDNA™ vaccine against human immunodeficiency virus (HIV) has activity in monkeys. The study, conducted by Drs. Yin Chen and Frédéric Kendirgi at CytoGenix in collaboration with Lauren Hirao and Dr. David Weiner of the University of Pennsylvania, demonstrated that rhesus monkeys injected with a synDNA™ HIV vaccine mounted a significant cellular immune response. The study involved monkeys treated with a synDNA™ vaccine targeting two key viral proteins (gag and env) with interleukin-15 as an adjuvant.
"This observation, the first evidence of activity for a synDNA™ vaccine in non-human primates, is encouraging in that it shows that the synDNA™ vaccine is as effective as the DNA plasmid-based vaccine expressing the same antigen. The advantages of using DNA vaccines can be significantly extended using synDNA™ constructs and warrants further study to determine if the response is sufficient to protect against HIV infection,” stated David B. Weiner, Ph.D., an expert in DNA vaccination and a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine.
-------------------------------------------------
Houston, TX (January 4, 2006) CytoGenix, Inc. (CYGX.OB) announced positive results of an animal study designed and conducted by the laboratory of Dr. David Weiner at the University of Pennsylvania Medical School Philadelphia. These tests demonstrated that a Cytogenix technique for generating synthetic DNA vaccines called synDNA™ as an smallpox vaccine, was highly potent in generating an immune response.
DNA vaccines are comprised of genes that confer immunologic protection by producing antigens without the need to expose the body to pathogenic organisms. For this study, Cytogenix scientists prepared a synDNA™ vaccine containing a gene sequence provided by Dr. Weiner that produces a protein that is an essential component of the smallpox virus.
Scientists in Dr. Weiner's laboratory tested and compared levels of antibodies and killer T cells produced in mice by the synDNA™ smallpox vaccine to a traditional plasmid DNA vaccine. The synDNA™ vaccine generated immunoglobulin and T cell levels in test animals several times greater than a comparable plasmid DNA vaccine produced by bacterial fermentation.
Dr. David B. Weiner, Associate Professor, University of Pennsylvania Medical School, Department of Pathology and Laboratory Medicine, a leading expert in DNA vaccines, commented, "we are impressed with the results from this study, the data, while preliminary are exciting".
AI
Market Data 
Markets 
